Transcription factors’ intrinsic disorder and lack of small molecule binding pockets make them difficult to drug, but one modality that has shown potential to target them is cyclic peptides.
In this talk, Dr. Gardner will explore how Curve Therapeutics integrated the Dianthus instrument with Spectral Shift technology into their screening cascade to validate cyclic peptide hits. He’ll present results with a focus on assay development, affinity screening, and data processing.
The decisions you make about your biologics candidates early in the pipeline ultimately affect their success as therapeutics. Combine sizing and stabi...
Carrie Haslam
This video reviews the uses and advantages of reporter cell lines in the context of cellular research and drug discovery....
Carrie Haslam
Watch Dr David Rimm from the Yale School of Medicine talk about his recent work and take on the future of multiplex spatial profiling of the TME....
Carrie Haslam
The pipetting robot, flowbot® ONE, is available with a HEPA filter to make clean-up processes easy and effective, enabling you to keep your samples sa...
Carrie Haslam
Dr. Stokes, Associate Director Proteomics, discusses how proteomic studies can increase effectiveness, speed of target and biomarker identification....
Carrie Haslam
Check out our library of NGS-related webinars from global researchers and industry professionals to explore possibilities with our Biomek automated wo...
Drug Target Review
Droplet Digital PCR (ddPCR) offers greater accuracy and precision in quantifying viral titer in gene therapies....
Carrie Haslam
...
Drug Target Review
Unlock Exclusive Industry Insights